NCT04971018Completed
Impact of Transcutaneous Auricular Vagus Nerve Stimulation on Digestive Symptoms in Systemic Sclerosis Systemic Sclerosis
Impact of Transcutaneous Auricular Vagus Nerve Stimulation on Digestive Symptoms in Systemic Sclerosis
Source: ClinicalTrials.gov · Last updated 6 Dec 2024
Brief summary (registry, in English)
The purpose of this study is to assess the effect of transcutaneous auricular vagus nerve stimulation (ta-VNS) on gastrointestinal symptoms and quality of life in systemic sclerosis (SSc) patients.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 20 (actual)
- First submitted
- 2 Jul 2021
- Start date
- 9 Nov 2021
- Primary completion date
- 15 May 2024
- Lead sponsor
- University Hospital, Grenoble
- Diseases
- Systemic sclerosis (scleroderma)
- NCT number
- NCT04971018
What you commit to
- Study type: Interventional
- Participants enrolled: 20
- From 9 Nov 2021 to the primary completion date, 15 May 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have previously received central or peripheral neurostimulation treatment regardless of indication.
- People with a cochlear implant near the stimulation site
Other illness
- People with dermatological disease in the area of application of stimulation electrodes
- People with recent venous or arterial thrombosis (less than one month)
- People followed for proven heart disease
Other
- People equipped with an active pacemaker in the area of application of the stimulation electrodes.
- Person who are protected under the act
- Pregnant or breastfeeding woman
Who the study is looking for
- SSc meeting ACR-EULAR (American College of Rheumatology- European League Against Rheumatism) criteria.
- Treatment by proton pump inhibitor (PPI) initiated for at least 3 months.
- Patient's written consent
- Affiliated with social security system
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| vascular medicine department, University hospital Coordinator of this site? Confirm its status | Grenoble | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.